Recent advancements in drug treatment of obesity

被引:43
作者
Carter, Rebeca [1 ]
Mouralidarane, Angelina [1 ]
Ray, Shuvra [1 ,2 ]
Soeda, Junpei [1 ]
Oben, Jude [1 ]
机构
[1] UCL, Royal Free Hosp, Ctr Liver & Digest Hlth, London WC1E 6BT, England
[2] Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol, London, England
关键词
Obesity; pharmacotherapy; WEIGHT-LOSS; MULTICENTER; EFFICACY;
D O I
10.7861/clinmedicine.12-5-456
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of obesity is rising worldwide, with the UK having the highest prevalence in Europe. Obesity is associated with significant morbidity and has substantial healthcare implications, with current projections estimating that by 2030 obesity will cost the NHS approximately 2 pound billion each year. Lifestyle modification remains the cornerstone of anti-obesity treatment, but drugs can be introduced as adjuncts to assist and maintain weight loss. Some 1.45 million obesity-related prescriptions were dispensed in 2009, highlighting the high demand for obesity pharmacotherapy. At present, the lipase inhibitor orlistat (Xenical) is the only UK-approved long-term medical therapy for obesity. Double-blind clinical trials have shown that orlistat significantly increases weight loss compared to placebo, but the array of adverse side effects associated with orlistat limits its tolerability. The need for more effective and better-tolerated anti-obesity medications is clear and six therapies have reached phase-III trials.
引用
收藏
页码:456 / 460
页数:5
相关论文
共 24 条
[1]  
[Anonymous], GUID PREV ID ASS MAN
[2]  
[Anonymous], STAT OB PHYS ACT DIE
[3]   Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].
Astrup, Arne ;
Rossner, Stephan ;
Van Gaal, Luc ;
Rissanen, Aila ;
Niskanen, Leo ;
Al Hakim, Mazin ;
Madsen, Jesper ;
Rasmussen, Mads F. ;
Lean, Michael E. J. .
LANCET, 2009, 374 (9701) :1606-1616
[4]   Medicinal strategies in the treatment of obesity [J].
Bray, GA ;
Tartaglia, LA .
NATURE, 2000, 404 (6778) :672-677
[5]  
Department of Health Public Health, 2011, OB GEN INF
[6]  
European Medicines Agency, 2011, EUR MED AG STARTS RE
[7]   BioEnterics Intragastric Balloon: The Italian experience with 2,515 patients [J].
Genco, A ;
Bruni, T ;
Doldi, SB ;
Forestieri, P ;
Marino, M ;
Busetto, L ;
Giardiello, C ;
Angrisani, L ;
Pecchioli, L ;
Stornelli, P ;
Puglisi, F ;
Alkilani, M ;
Nigri, A ;
Di Lorenzo, N ;
Furbetta, F ;
Cascardo, A ;
Cipriano, M ;
Lorenzo, M ;
Basso, N .
OBESITY SURGERY, 2005, 15 (08) :1161-1164
[8]   Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].
Greenway, Frank L. ;
Fujioka, Ken ;
Plodkowski, Raymond A. ;
Mudaliar, Sunder ;
Guttadauria, Maria ;
Erickson, Janelle ;
Kim, Dennis D. ;
Dunayevich, Eduardo .
LANCET, 2010, 376 (9741) :595-605
[9]  
Hurt Ryan T, 2011, JPEN J Parenter Enteral Nutr, V35, p4S, DOI 10.1177/0148607111415110
[10]   Pharmacotherapies for Obesity: Past, Current, and Future Therapies [J].
Ioannides-Demos, Lisa L. ;
Piccenna, Loretta ;
McNeil, John J. .
JOURNAL OF OBESITY, 2011, 2011